Trials / Terminated
TerminatedNCT06447506
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1070806 | Participants will receive GSK1070806. |
Timeline
- Start date
- 2024-06-05
- Primary completion
- 2025-07-29
- Completion
- 2025-07-29
- First posted
- 2024-06-07
- Last updated
- 2025-11-17
Locations
51 sites across 15 countries: United States, Argentina, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Japan, Mexico, Panama, Poland, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06447506. Inclusion in this directory is not an endorsement.